Related Experiment Videos
Effect of captopril therapy on lymphocyte potassium and magnesium concentrations in patients with congestive heart
1Department of Cardiology, University College Hospital, Galway, Ireland.
Insights
Captopril treatment increased lymphocyte potassium and magnesium in heart failure patients on diuretics. This suggests a potential mechanism for how these drugs improve survival and reduce arrhythmias.
Area of Science:
- Cardiology
- Pharmacology
- Cellular Physiology
Background:
- Congestive heart failure (CHF) patients on diuretics often experience electrolyte imbalances.
- Diuretic therapy can lead to decreased intracellular potassium and magnesium levels.
- Angiotensin-converting enzyme (ACE) inhibitors are crucial in managing CHF.
Purpose of the Study:
- To investigate the effect of captopril on lymphocyte potassium and magnesium levels in CHF patients.
- To explore the potential role of intracellular electrolytes in ACE inhibitor efficacy.
Main Methods:
- Lymphocyte potassium and magnesium were measured before and after 3 months of captopril treatment.
- Patients were categorized based on diuretic regimen (potassium supplements plus frusemide, or potassium-sparing combination).
- Comparison was made with healthy controls.
Main Results:
- Patients on potassium supplements plus frusemide showed decreased baseline lymphocyte magnesium and potassium compared to controls.
- Captopril treatment significantly increased both lymphocyte potassium and magnesium in these patients.
- Patients on potassium-sparing diuretics also exhibited increased lymphocyte magnesium after captopril initiation.
Conclusions:
- Captopril therapy may restore intracellular potassium and magnesium levels in CHF patients.
- Increased intracellular electrolytes could be a mechanism by which ACE inhibitors reduce arrhythmias.
- This mechanism may contribute to improved survival rates in congestive heart failure patients treated with ACE inhibitors.
Abstract:
Lymphocyte potassium and magnesium were measured before and 3 months after the introduction of captopril in 18 patients taking diuretics for congestive heart failure. Compared to 32 healthy controls, 9 patients who had been on potassium supplements plus frusemide had decreased baseline lymphocyte magnesium and potassium concentrations (p less than 0.01), in spite of similar plasma electrolyte levels. There was a significant (p less than 0.01) increase in both lymphocyte potassium and magnesium levels after 3 months' treatment with captopril and frusemide in these patients. Nine patients who had been taking a potassium-sparing combination diuretic also had an increase in lymphocyte magnesium (p less than 0.05) following the introduction of captopril. Increased intracellular potassium and magnesium may be one mechanism whereby angiotensin-converting enzyme inhibitors reduced arrhythmias and improve survival in patients with congestive heart failure.